Total: £ 56.28
Published Date: 2022-06-23 | Pages: 93 | Tables: 141 | Pharma & Healthcare
Calcium antagonists are a group of medications that disrupt the movement of calcium (Ca2+) through calcium channels. Calcium channel blockers are used as antihypertensive drugs, i.e., as medications to decrease blood pressure in patients with hypertension. CCBs are particularly effective against large vessel stiffness, one of the common causes of elevated systolic blood pressure in elderly patients. Calcium channel blockers are also frequently used to alter heart rate (especially from atrial fibrillation), to prevent peripheral and cerebral vasospasm, and to reduce chest pain caused by angina pectoris. N-type, L-type, and T-type voltage-dependent calcium channels are present in the zona glomerulosa of the human adrenal gland, and CCBs can directly influence the biosynthesis of aldosterone in adrenocortical cells, with consequent impact on the clinical treatment of hypertension with these agents. CCBs have been shown to be slightly more effective than beta blockers at lowering cardiovascular mortality, but they are associated with more side effects. Potential major risks however were mainly found to be associated with short-acting CCBs.
Due to the COVID-19 pandemic, the global Calcium Antagonists market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Calcium Antagonists market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Calcium Antagonists landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Dihydropyridine accounting for % of the Calcium Antagonists global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hypertension segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Calcium Antagonists include Pfizer, Aventis, Searle, Bayer, AstraZeneca, Knoll Pharmaceuticals, Wyeth-Ayerst, Novartis and Sanofi, etc. In terms of revenue, the global 3 largest players have a % market share of Calcium Antagonists in 2021.
This report focuses on Calcium Antagonists volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Calcium Antagonists market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Calcium Antagonists Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Dihydropyridine
Diltiazem
Verapamil
Others
Segment by Application
Hypertension
Coronary Artery Disease
Arrhythmia
Ohers
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Pfizer
Aventis
Searle
Bayer
AstraZeneca
Knoll Pharmaceuticals
Wyeth-Ayerst
Novartis
Sanofi
Baiyunshan Pharmaceutical
South China Pharmaceutical Group
Tianjin Tanabe Seiyaku
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Calcium Antagonists Market Overview
1.1 Product Overview and Scope of Calcium Antagonists
1.2 Calcium Antagonists Segment by Type
1.2.1 Global Calcium Antagonists Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Dihydropyridine
1.2.3 Diltiazem
1.2.4 Verapamil
1.2.5 Others
1.3 Calcium Antagonists Segment by Application
1.3.1 Global Calcium Antagonists Sales Comparison by Application: (2022-2028)
1.3.2 Hypertension
1.3.3 Coronary Artery Disease
1.3.4 Arrhythmia
1.3.5 Ohers
1.4 Global Calcium Antagonists Market Size Estimates and Forecasts
1.4.1 Global Calcium Antagonists Revenue 2017-2028
1.4.2 Global Calcium Antagonists Sales 2017-2028
1.4.3 Calcium Antagonists Market Size by Region: 2017 Versus 2021 Versus 2028
2 Calcium Antagonists Market Competition by Manufacturers
2.1 Global Calcium Antagonists Sales Market Share by Manufacturers (2017-2022)
2.2 Global Calcium Antagonists Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Calcium Antagonists Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Calcium Antagonists Manufacturing Sites, Area Served, Product Type
2.5 Calcium Antagonists Market Competitive Situation and Trends
2.5.1 Calcium Antagonists Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Calcium Antagonists Players Market Share by Revenue
2.5.3 Global Calcium Antagonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Calcium Antagonists Retrospective Market Scenario by Region
3.1 Global Calcium Antagonists Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Calcium Antagonists Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Calcium Antagonists Market Facts & Figures by Country
3.3.1 North America Calcium Antagonists Sales by Country
3.3.2 North America Calcium Antagonists Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Calcium Antagonists Market Facts & Figures by Country
3.4.1 Europe Calcium Antagonists Sales by Country
3.4.2 Europe Calcium Antagonists Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Calcium Antagonists Market Facts & Figures by Region
3.5.1 Asia Pacific Calcium Antagonists Sales by Region
3.5.2 Asia Pacific Calcium Antagonists Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Calcium Antagonists Market Facts & Figures by Country
3.6.1 Latin America Calcium Antagonists Sales by Country
3.6.2 Latin America Calcium Antagonists Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Calcium Antagonists Market Facts & Figures by Country
3.7.1 Middle East and Africa Calcium Antagonists Sales by Country
3.7.2 Middle East and Africa Calcium Antagonists Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Calcium Antagonists Historic Market Analysis by Type
4.1 Global Calcium Antagonists Sales Market Share by Type (2017-2022)
4.2 Global Calcium Antagonists Revenue Market Share by Type (2017-2022)
4.3 Global Calcium Antagonists Price by Type (2017-2022)
5 Global Calcium Antagonists Historic Market Analysis by Application
5.1 Global Calcium Antagonists Sales Market Share by Application (2017-2022)
5.2 Global Calcium Antagonists Revenue Market Share by Application (2017-2022)
5.3 Global Calcium Antagonists Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Calcium Antagonists Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Pfizer Calcium Antagonists Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Aventis
6.2.1 Aventis Corporation Information
6.2.2 Aventis Description and Business Overview
6.2.3 Aventis Calcium Antagonists Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Aventis Calcium Antagonists Product Portfolio
6.2.5 Aventis Recent Developments/Updates
6.3 Searle
6.3.1 Searle Corporation Information
6.3.2 Searle Description and Business Overview
6.3.3 Searle Calcium Antagonists Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Searle Calcium Antagonists Product Portfolio
6.3.5 Searle Recent Developments/Updates
6.4 Bayer
6.4.1 Bayer Corporation Information
6.4.2 Bayer Description and Business Overview
6.4.3 Bayer Calcium Antagonists Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Bayer Calcium Antagonists Product Portfolio
6.4.5 Bayer Recent Developments/Updates
6.5 AstraZeneca
6.5.1 AstraZeneca Corporation Information
6.5.2 AstraZeneca Description and Business Overview
6.5.3 AstraZeneca Calcium Antagonists Sales, Revenue and Gross Margin (2017-2022)
6.5.4 AstraZeneca Calcium Antagonists Product Portfolio
6.5.5 AstraZeneca Recent Developments/Updates
6.6 Knoll Pharmaceuticals
6.6.1 Knoll Pharmaceuticals Corporation Information
6.6.2 Knoll Pharmaceuticals Description and Business Overview
6.6.3 Knoll Pharmaceuticals Calcium Antagonists Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Knoll Pharmaceuticals Calcium Antagonists Product Portfolio
6.6.5 Knoll Pharmaceuticals Recent Developments/Updates
6.7 Wyeth-Ayerst
6.6.1 Wyeth-Ayerst Corporation Information
6.6.2 Wyeth-Ayerst Description and Business Overview
6.6.3 Wyeth-Ayerst Calcium Antagonists Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Wyeth-Ayerst Calcium Antagonists Product Portfolio
6.7.5 Wyeth-Ayerst Recent Developments/Updates
6.8 Novartis
6.8.1 Novartis Corporation Information
6.8.2 Novartis Description and Business Overview
6.8.3 Novartis Calcium Antagonists Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Novartis Calcium Antagonists Product Portfolio
6.8.5 Novartis Recent Developments/Updates
6.9 Sanofi
6.9.1 Sanofi Corporation Information
6.9.2 Sanofi Description and Business Overview
6.9.3 Sanofi Calcium Antagonists Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Sanofi Calcium Antagonists Product Portfolio
6.9.5 Sanofi Recent Developments/Updates
6.10 Baiyunshan Pharmaceutical
6.10.1 Baiyunshan Pharmaceutical Corporation Information
6.10.2 Baiyunshan Pharmaceutical Description and Business Overview
6.10.3 Baiyunshan Pharmaceutical Calcium Antagonists Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Baiyunshan Pharmaceutical Calcium Antagonists Product Portfolio
6.10.5 Baiyunshan Pharmaceutical Recent Developments/Updates
6.11 South China Pharmaceutical Group
6.11.1 South China Pharmaceutical Group Corporation Information
6.11.2 South China Pharmaceutical Group Calcium Antagonists Description and Business Overview
6.11.3 South China Pharmaceutical Group Calcium Antagonists Sales, Revenue and Gross Margin (2017-2022)
6.11.4 South China Pharmaceutical Group Calcium Antagonists Product Portfolio
6.11.5 South China Pharmaceutical Group Recent Developments/Updates
6.12 Tianjin Tanabe Seiyaku
6.12.1 Tianjin Tanabe Seiyaku Corporation Information
6.12.2 Tianjin Tanabe Seiyaku Calcium Antagonists Description and Business Overview
6.12.3 Tianjin Tanabe Seiyaku Calcium Antagonists Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Tianjin Tanabe Seiyaku Calcium Antagonists Product Portfolio
6.12.5 Tianjin Tanabe Seiyaku Recent Developments/Updates
7 Calcium Antagonists Manufacturing Cost Analysis
7.1 Calcium Antagonists Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Calcium Antagonists
7.4 Calcium Antagonists Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Calcium Antagonists Distributors List
8.3 Calcium Antagonists Customers
9 Calcium Antagonists Market Dynamics
9.1 Calcium Antagonists Industry Trends
9.2 Calcium Antagonists Market Drivers
9.3 Calcium Antagonists Market Challenges
9.4 Calcium Antagonists Market Restraints
10 Global Market Forecast
10.1 Calcium Antagonists Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Calcium Antagonists by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Calcium Antagonists by Type (2023-2028)
10.2 Calcium Antagonists Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Calcium Antagonists by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Calcium Antagonists by Application (2023-2028)
10.3 Calcium Antagonists Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Calcium Antagonists by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Calcium Antagonists by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Calcium Antagonists Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Calcium Antagonists Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Calcium Antagonists Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Calcium Antagonists Market Competitive Situation by Manufacturers in 2021
Table 5. Global Calcium Antagonists Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Calcium Antagonists Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Calcium Antagonists Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Calcium Antagonists Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Calcium Antagonists Average Price (USD/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Calcium Antagonists Manufacturing Sites and Area Served
Table 11. Manufacturers Calcium Antagonists Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Calcium Antagonists by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Calcium Antagonists as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Calcium Antagonists Sales by Region (2017-2022) & (K Units)
Table 16. Global Calcium Antagonists Sales Market Share by Region (2017-2022)
Table 17. Global Calcium Antagonists Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Calcium Antagonists Revenue Market Share by Region (2017-2022)
Table 19. North America Calcium Antagonists Sales by Country (2017-2022) & (K Units)
Table 20. North America Calcium Antagonists Sales Market Share by Country (2017-2022)
Table 21. North America Calcium Antagonists Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Calcium Antagonists Revenue Market Share by Country (2017-2022)
Table 23. Europe Calcium Antagonists Sales by Country (2017-2022) & (K Units)
Table 24. Europe Calcium Antagonists Sales Market Share by Country (2017-2022)
Table 25. Europe Calcium Antagonists Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Calcium Antagonists Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Calcium Antagonists Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Calcium Antagonists Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Calcium Antagonists Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Calcium Antagonists Revenue Market Share by Region (2017-2022)
Table 31. Latin America Calcium Antagonists Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Calcium Antagonists Sales Market Share by Country (2017-2022)
Table 33. Latin America Calcium Antagonists Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Calcium Antagonists Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Calcium Antagonists Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Calcium Antagonists Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Calcium Antagonists Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Calcium Antagonists Revenue Market Share by Country (2017-2022)
Table 39. Global Calcium Antagonists Sales by Type (2017-2022) & (K Units)
Table 40. Global Calcium Antagonists Sales Market Share by Type (2017-2022)
Table 41. Global Calcium Antagonists Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Calcium Antagonists Revenue Share by Type (2017-2022)
Table 43. Global Calcium Antagonists Price by Type (2017-2022) & (USD/Unit)
Table 44. Global Calcium Antagonists Sales (K Units) by Application (2017-2022)
Table 45. Global Calcium Antagonists Sales Market Share by Application (2017-2022)
Table 46. Global Calcium Antagonists Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Calcium Antagonists Revenue Share by Application (2017-2022)
Table 48. Global Calcium Antagonists Price by Application (2017-2022) & (USD/Unit)
Table 49. Pfizer Corporation Information
Table 50. Pfizer Description and Business Overview
Table 51. Pfizer Calcium Antagonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 52. Pfizer Calcium Antagonists Product
Table 53. Pfizer Recent Developments/Updates
Table 54. Aventis Corporation Information
Table 55. Aventis Description and Business Overview
Table 56. Aventis Calcium Antagonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 57. Aventis Calcium Antagonists Product
Table 58. Aventis Recent Developments/Updates
Table 59. Searle Corporation Information
Table 60. Searle Description and Business Overview
Table 61. Searle Calcium Antagonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 62. Searle Calcium Antagonists Product
Table 63. Searle Recent Developments/Updates
Table 64. Bayer Corporation Information
Table 65. Bayer Description and Business Overview
Table 66. Bayer Calcium Antagonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 67. Bayer Calcium Antagonists Product
Table 68. Bayer Recent Developments/Updates
Table 69. AstraZeneca Corporation Information
Table 70. AstraZeneca Description and Business Overview
Table 71. AstraZeneca Calcium Antagonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 72. AstraZeneca Calcium Antagonists Product
Table 73. AstraZeneca Recent Developments/Updates
Table 74. Knoll Pharmaceuticals Corporation Information
Table 75. Knoll Pharmaceuticals Description and Business Overview
Table 76. Knoll Pharmaceuticals Calcium Antagonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 77. Knoll Pharmaceuticals Calcium Antagonists Product
Table 78. Knoll Pharmaceuticals Recent Developments/Updates
Table 79. Wyeth-Ayerst Corporation Information
Table 80. Wyeth-Ayerst Description and Business Overview
Table 81. Wyeth-Ayerst Calcium Antagonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 82. Wyeth-Ayerst Calcium Antagonists Product
Table 83. Wyeth-Ayerst Recent Developments/Updates
Table 84. Novartis Corporation Information
Table 85. Novartis Description and Business Overview
Table 86. Novartis Calcium Antagonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 87. Novartis Calcium Antagonists Product
Table 88. Novartis Recent Developments/Updates
Table 89. Sanofi Corporation Information
Table 90. Sanofi Description and Business Overview
Table 91. Sanofi Calcium Antagonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 92. Sanofi Calcium Antagonists Product
Table 93. Sanofi Recent Developments/Updates
Table 94. Baiyunshan Pharmaceutical Corporation Information
Table 95. Baiyunshan Pharmaceutical Description and Business Overview
Table 96. Baiyunshan Pharmaceutical Calcium Antagonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 97. Baiyunshan Pharmaceutical Calcium Antagonists Product
Table 98. Baiyunshan Pharmaceutical Recent Developments/Updates
Table 99. South China Pharmaceutical Group Corporation Information
Table 100. South China Pharmaceutical Group Description and Business Overview
Table 101. South China Pharmaceutical Group Calcium Antagonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 102. South China Pharmaceutical Group Calcium Antagonists Product
Table 103. South China Pharmaceutical Group Recent Developments/Updates
Table 104. Tianjin Tanabe Seiyaku Corporation Information
Table 105. Tianjin Tanabe Seiyaku Description and Business Overview
Table 106. Tianjin Tanabe Seiyaku Calcium Antagonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 107. Tianjin Tanabe Seiyaku Calcium Antagonists Product
Table 108. Tianjin Tanabe Seiyaku Recent Developments/Updates
Table 109. Production Base and Market Concentration Rate of Raw Material
Table 110. Key Suppliers of Raw Materials
Table 111. Calcium Antagonists Distributors List
Table 112. Calcium Antagonists Customers List
Table 113. Calcium Antagonists Market Trends
Table 114. Calcium Antagonists Market Drivers
Table 115. Calcium Antagonists Market Challenges
Table 116. Calcium Antagonists Market Restraints
Table 117. Global Calcium Antagonists Sales Forecast by Type (2023-2028) & (K Units)
Table 118. Global Calcium Antagonists Sales Market Share Forecast by Type (2023-2028)
Table 119. Global Calcium Antagonists Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 120. Global Calcium Antagonists Revenue Market Share Forecast by Type (2023-2028)
Table 121. Global Calcium Antagonists Sales Forecast by Application (2023-2028) & (K Units)
Table 122. Global Calcium Antagonists Sales Market Share Forecast by Application (2023-2028)
Table 123. Global Calcium Antagonists Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 124. Global Calcium Antagonists Revenue Market Share Forecast by Application (2023-2028)
Table 125. Global Calcium Antagonists Sales Forecast by Region (2023-2028) & (K Units)
Table 126. Global Calcium Antagonists Sales Market Share Forecast by Region (2023-2028)
Table 127. Global Calcium Antagonists Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 128. Global Calcium Antagonists Revenue Market Share Forecast by Region (2023-2028)
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Calcium Antagonists
Figure 2. Global Calcium Antagonists Market Share by Type in 2021 & 2028
Figure 3. Dihydropyridine Product Picture
Figure 4. Diltiazem Product Picture
Figure 5. Verapamil Product Picture
Figure 6. Others Product Picture
Figure 7. Global Calcium Antagonists Market Share by Application in 2021 & 2028
Figure 8. Hypertension
Figure 9. Coronary Artery Disease
Figure 10. Arrhythmia
Figure 11. Ohers
Figure 12. Global Calcium Antagonists Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Calcium Antagonists Market Size (2017-2028) & (US$ Million)
Figure 14. Global Calcium Antagonists Sales (2017-2028) & (K Units)
Figure 15. Calcium Antagonists Sales Share by Manufacturers in 2021
Figure 16. Global Calcium Antagonists Revenue Share by Manufacturers in 2021
Figure 17. The Global 5 and 10 Largest Calcium Antagonists Players: Market Share by Revenue in 2021
Figure 18. Calcium Antagonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 19. Global Calcium Antagonists Sales Market Share by Region (2017-2022)
Figure 20. Global Calcium Antagonists Sales Market Share by Region in 2021
Figure 21. Global Calcium Antagonists Revenue Market Share by Region (2017-2022)
Figure 22. Global Calcium Antagonists Revenue Market Share by Region in 2021
Figure 23. U.S. Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. Canada Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. Germany Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. France Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. U.K. Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. Italy Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. Russia Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. China Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. Japan Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. South Korea Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. India Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Australia Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Taiwan Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Indonesia Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Thailand Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Malaysia Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Philippines Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Vietnam Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Mexico Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Brazil Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. Argentina Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. Turkey Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 45. Saudi Arabia Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 46. U.A.E Calcium Antagonists Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 47. Sales Market Share of Calcium Antagonists by Type (2017-2022)
Figure 48. Manufacturing Cost Structure of Calcium Antagonists
Figure 49. Manufacturing Process Analysis of Calcium Antagonists
Figure 50. Calcium Antagonists Industrial Chain Analysis
Figure 51. Channels of Distribution
Figure 52. Distributors Profiles
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed